A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
22 Feb 2022
22 Feb 2022
Historique:
received:
13
12
2021
accepted:
10
02
2022
entrez:
15
4
2022
pubmed:
16
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
A simple, specific, selective and accurate bioanalytical method was developed and validated for simultaneous estimation of acalabrutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Deuterated analogs of both the analytes were used as internal standards. The extraction of analytes and internal standards were evaluated from the human plasma by liquid-liquid extraction technique using methyl tertiary butyl ether (TBME). The separation of the analytes was carried out on Zorbax Eclipse XDB-C
Identifiants
pubmed: 35424612
doi: 10.1039/d1ra09026g
pii: d1ra09026g
pmc: PMC8982068
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6631-6639Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
J Pharm Biomed Anal. 2020 Nov 30;191:113613
pubmed: 32971496
Drugs. 2018 Jan;78(1):139-145
pubmed: 29209955
Future Oncol. 2019 Feb;15(6):579-589
pubmed: 30381956
Blood. 2004 Jun 15;103(12):4389-95
pubmed: 14962897
J Pharm Biomed Anal. 2016 Jan 25;118:123-131
pubmed: 26540627
N Engl J Med. 2016 Jan 28;374(4):323-32
pubmed: 26641137
J Pharm Biomed Anal. 2019 Feb 5;164:509-513
pubmed: 30453157
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 15;1137:121928
pubmed: 31877431
Drug Metab Dispos. 2019 Feb;47(2):145-154
pubmed: 30442651
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
J Pharm Biomed Anal. 2015 Mar 25;107:151-8
pubmed: 25594893